CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

NCT02132624 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma
B Cell Leukemia

Interventions

BIOLOGICAL: Autologous 3rd generation CD19-targeting CAR T cells

Sponsor

Uppsala University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]